

PIG 2 . 50 30 10 ATGAAAAAAACAAAACTTATTTTTTTTTTTTACTTCAATATTTCATTGCAATAATTTCTCGT MKKTKLIFSFTSIFIAIISR 90 70 CCTGTGTTTGGATTAGAAGTAGATAATAATTCCCTTCTAAGGAATATCTATAGTACGATT P V F G L E V D N N S L L R N I Y S T I 150 GTATATGAATATTCAGATATAGTAATTGATTTTAAAACCAGTCATAACTTAGTGACTAAG V Y E Y S D I V I .D F K T S H N L V T K 210 AAACTTGATGTTAGAGATGCTAGAGATTTCTTTATTAACTCCGAAATGGACGAATATGCA K L D V R D A R D F F I N S E M D E Y A 290. 270 GCCAATGATTTTAAAACTGGAGATAAAATAGCTGTGTTCTCCGTCCCATTTGATTGGAAC ANDFKTGDKIAVFSVPFDWN 350 330 310 TATTTATCAAAAGGAAAAGTCACAGCATATACCTATGGTGGAATAACACCCTACCAAAAA YLSKGKVTAYTYGGITPYQK 390 370 ACTTCAATACCTAAAAAtatCCCTGTTAATTTATGGattaatGgAAAGcagatCTCTgtT T S I P K N I P V N L W I N G K Q I S V 450 CCTtaCaaCGAAATATCaaCTAACAAAACAacaGTTACAGCTCAAGAAAttgATCTAAAG PYNE.ISTNKTTVTAQEIDLK 510 490 GTTAGAAAATTTTTAATAGCACAACATCAATTATATTCTTCTGGTTCTAGCTACAAAAGT VRKFLIAQHQLYSSGSSYKS 590 570 550 GGTAGACTGGTTTTTCATACAAATGATAATTCAGATAAATATTCTTTCgatcTTTTctat G R L V F H T N D N S D K Y S F D L F Y 630

670 690



Applicant(s): John D. Fraser, et al. SUPERANTIGENS



SPE-G

FIG 3

									FIG	3									
			10						30)						50			
ATGAAAACAATTTTGACAATTATCATATTATCATGTGTTTTTTAGCTATGGAAGTCAA																			
М	K	T	N	I	L	T	I	I	I	L	S	С	٧	F	s	Y	G	s	Q
			70						90)						110			
. TTAGCTTATGCAGATGAAAATTTAAAAGATTTAAAAAGAAGTTTAAGATTTGCCTATA																			
TT L	AGC A	TTA Y	TGC A	AGA D	TGA E	aaa N	TTT L		AGA1 D		aaa K	AAG. R	AAG S		AAC R	ATT F	TGC A	CTA Y	TAAT N
_	^	٠	^	-	-	41	_		-	_	••	•	•	_	•	•	•	•	.,
		1	30						1.50)						170			
» ጥ	ጥክሮ	ccc	እጥር	CCX	ጥጥአ	TC D	מממ	ጥርጥ	AGAA	a Tr	rec	ישים ע	· rct	ጥ አ ር ፡	ጉ ልር		ጥአር	ር አ ጥ	מרמת
I	T	P	C	D	Y			v	E		A	F	v	T	T	N	S	I	H
		1	90						210)						230			
ΑТ	TAA'	TAC	TAA	ACA	AAA	AAG	ATC	GGA	ATGT	'AT	rct'	rta'	TGT	TGA	TTC	TAT	TGT.	ATC	TTTA
I	N	T	к	Q	к	R		E	С			Y	ν		s	I	ν	s	L
		2	50						270)						290			
GG	CAT'	TAC'	TGA	TCA	GTT	TAT.	AAA	AGG	GGAT	'AA	GGT	CGA'	Igt	TTT'	rge	TCT	CCC	TTA	Taat
G	I	T	D	Q	F	I	K	G	D	ĸ	v	D	V	F	G	L	P	Y	N
		_							220							250			
		3	10			_			330							350			_
TT	TTC	CCC.	ACC	TTA	TGT.	AGA	TAA	TAT	TTAT	GG?	rgg:	TAT	rgt:	AAA	ACA	TTC	GAA	TCA	AGGA
F	S	P	P	Y	v	D	N	I	Y	G	G	I	ν	K	H	S	N	Q	G
		3	70						390							410			
		,														410			
AA'	IAA I	ATC	ATT.	ACA	GTT	TGT.	AGG.		ATTT		CA	AGA'	rgg		AG A	AAC	TTA	TTT	GCCC
N	K	S	L	Q	F	V	G	I	L	N	Q	D	G	K	E	Т	Y	L	P
		4	30						450							470			
			•													•			
	-															-			ATAA
S	E	A	V	R	I	K	K	K	Q	F	T	L	Q	E	F	D	F	K	I
		4 :	90						510							530			
													•						
		_	-						TATC										
R	K	F	L	M	E	K	Y	N	I.	Y	D	S	E	S	R	Y	T	S	G
		5	50						570							590			
			•			•													
	CCT: L								TAAA K										GGAT
3	7	ŗ	ш	^	•	v	ע	3	N.	n	1	Ę.	٧	٠.	ע	r	14	n	U
		6	10						630							650			
			•																
									CTTT. F										TAAT N
	**	-	~	J	**	-	-	•	•		••	•	••	-	••	•,	•	•	••
		6	70						690										
D C.	י מים	\ C N 1		m » ~	יי איי		ימים	T A T	-m»	ጥጥን		\ N ~ 4		י מידים	~				
									CTAC						•				





SPE-H

TC A

10		30	50
ATGAGATATAAT	PGTCGCTACTCAC	ATATTGATAAGA	AAATCTACAGCATGATTATATGT
MRYNO	C R Y S H	I D K K	IYSMIIC
70		. 90	. 110
TTGTCATTTCTT	TTATATTCCAATG	FTGTTCAAGCAA	ATTCTTATAATACAACCAATAGA
		V Q A N	
130		150	170
CATAATCTAGAAT	CCCTTTATAAGC	ATGATTCTAACT	AAAATTGAAGCCGATAGTATAAA
	S L Y K H		
190		210	230
AATTCTCCAGATA			ATAGTGTCAAGGATAAAAATTTC
N S P D I	гутѕн	MLKY	SVKDKNL
250		270	290
		TATCACAGGAAT S O E F	TCAAAGATAAAGAAGTAGATATT K D K E V D I
SVFFE	EKDWI	_	
310		330	350
	CACAAGAGGTTTC	TGAATGTCCAG E C P G	GGAAAAGGTATGAAGCGTTtggt KRYEAFG
	. Q E V C		
370		390	410
GGAATTACATTAA G I T L T			AAGTTCCTGTAAACGtgtGggat V P V N V W D
430		450	470
• • • • • • • • • • • • • • • • • • • •	AGCCGCCTATGTT		ATAAACCGAAagtaaCCGC TC AG K P K V T A Q
		510	530
490		•	
GAAGTGGATATAA E V D I K			aatacgATATCTATAATAaccgg Y D I Y N N R
550		570	590
			TAAATTCAGGTAAAGATATTGTT
E Q K Y S	K G T V	T L D L	N S G K D I V
610		630	650
TTTGATTTGTATT	ATTTTGGCAATGO	BAGACTTTAATA	GCATGCTAAAAATATATTCCAA
	F G N G	D F N S	
670		690	710
AACGAGAGAATAG	GactcaactCAATI	TCATGTAGatg	TGTCaatcagctaA
NERTO			



Applicant(s): John D. Fraser, et al. SUPERANTIGENS



SPE-J (partial)


FIG 5


10								30							50					
CTTCCGTACATATTTACTCGTTATGATGTTTATTATATATA													ATCA							
ī.		Y		F	T	R		p			Ÿ					٧	T		S	
-	•	•	-	-	•	••	-	_	-	_	_	_	_		_		_	_	-	
			70						ġ	Ď						110				
GTAAACAGTAATTCGGAAAATÁGTAAÁAT										١.			•			ě			•	
GT																				
٧	N	5	N	ŝ	Ε	N	ŝ	ĸ	1	٧	Ĝ	N	Ľ	Ŀ	I	D	G	٧	Q	
130									15	0						170				
CD	מממ	אאר	Дст	דממ	מממ	тсс тсс	CAT	444	דעע	DCD	ממד	ACC	TAT	ተ ተጉ	TAC	GAT	тса	AGA	ATTT	
<u>ح</u>		T		ī	N	P		K		D			ï	F	T	I	0		F	
*	*	•	~	•	••	•	•	••	-	_	••	•	_	•	-	_	-		-	
		1	90						210						230					
			•			•				•			•						•	
GΑ	CTT			CAG	ACA		-												TCCA	
D	F	K	I	R	Q	Y	L	M	Q	T	Y	K	I	Y	D	P	N	S	P	
		2	50						270						290					
			•			•				•			•			•			:	
TA																			CTTA	
Y	I	K	G	Q	L	E	I	A	I	N	G	N	K	H	E	S	F	N	L	
310							330						350							
			•			_ ·				•			_:-					a- v		
						TAG S							TAA K			VI'AA K	AGA D	N N	DAAT.	
Y	D	A	T	9	5	S	Ť	ĸ	\$.	ע	1	r	Λ.	Λ.	1	v	U	14	N.	
370								39	390 410											
20	ACTATAAATATGAAAGATTTCAGCCATTTTGATATTTACCTTtggACTAAATAA																			
~		-												w	-					






PIG 6











Applin No.: 09/869,136 Applicant(s): John D. Fraser, et al. SUPERANTIGENS



FIG











PIG 8








Appin No.: 09/869,136 Applicant(s): John D. Fraser, et al. SUPERANTIGENS




FIG 9





Appln 09/869,136 Applicant(s): John D. Fraser, et al. SUPERANTIGENS

PIG 10





Applicant(s): John D. Fraser, et al. SUPERANTIGENS

Fig. 11

unlabeled toxins

		SMEZ	SMEZ-2	SPE-G	SPE-H	SEB	TSST	SEA	SPE-C
	SMEZ								
	SMEZ-2								
SI	SPE-G								
tracer toxins	SPE-H								
trace	SEB								
	TSST								
	SEA	(A)							
	SPE-C								



Appln No.: 09/869,136 Applicant(s): John D. Fraser, et al. SUPERANTIGENS

PIG 12






FIG 13

